메뉴 건너뛰기




Volumn 161, Issue 5, 2013, Pages 667-676

Inhibition of related JAK/STAT pathways with molecular targeted drugs shows strong synergy with ruxolitinib in chronic myeloproliferative neoplasm

Author keywords

Drug synergisms; KNK437; Myeloproliferative disease; Ruxolitinib; Stem cells

Indexed keywords

ANTINEOPLASTIC AGENT; DASATINIB; JANUS KINASE; JANUS KINASE 2; KNK 437; MITOGEN ACTIVATED PROTEIN KINASE P38; PERIFOSINE; RUXOLITINIB; SORAFENIB; STAT5 PROTEIN; UNCLASSIFIED DRUG;

EID: 84877832281     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12308     Document Type: Article
Times cited : (22)

References (36)
  • 7
    • 84857007592 scopus 로고    scopus 로고
    • Sorafenib-induced apoptosis of chronic lymphocytic leukemia cells is associated with downregulation of RAF and myeloid cell leukemia sequence 1 (Mcl-1)
    • Fecteau, J.F., Bharati, I.S., O'Hayre, M., Handel, T.M., Kipps, T.J. & Messmer, D. (2012) Sorafenib-induced apoptosis of chronic lymphocytic leukemia cells is associated with downregulation of RAF and myeloid cell leukemia sequence 1 (Mcl-1). Molecular Medicine, 18, 19-28.
    • (2012) Molecular Medicine , vol.18 , pp. 19-28
    • Fecteau, J.F.1    Bharati, I.S.2    O'Hayre, M.3    Handel, T.M.4    Kipps, T.J.5    Messmer, D.6
  • 9
    • 84855879102 scopus 로고    scopus 로고
    • Proteomic study identified HSP 70 kDa protein 1A as a possible therapeutic target, in combination with histone deacetylase inhibitors, for lymphoid neoplasms
    • Fujii, K., Suzuki, N., Ikeda, K., Hamada, T., Yamamoto, T., Kondo, T. & Iwatsuki, K. (2012) Proteomic study identified HSP 70 kDa protein 1A as a possible therapeutic target, in combination with histone deacetylase inhibitors, for lymphoid neoplasms. Journal of Proteomics, 75, 1401-1410.
    • (2012) Journal of Proteomics , vol.75 , pp. 1401-1410
    • Fujii, K.1    Suzuki, N.2    Ikeda, K.3    Hamada, T.4    Yamamoto, T.5    Kondo, T.6    Iwatsuki, K.7
  • 11
    • 84863283404 scopus 로고    scopus 로고
    • Molecular targeted therapies for cancer: sorafenib mono-therapy and its combination with other therapies (review)
    • Ibrahim, N., Yu, Y., Walsh, W.R. & Yang, J.L. (2012) Molecular targeted therapies for cancer: sorafenib mono-therapy and its combination with other therapies (review). Oncology Reports, 27, 1303-1311.
    • (2012) Oncology Reports , vol.27 , pp. 1303-1311
    • Ibrahim, N.1    Yu, Y.2    Walsh, W.R.3    Yang, J.L.4
  • 13
    • 25844432737 scopus 로고    scopus 로고
    • Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2
    • Kralovics, R., Teo, S.S., Buser, A.S., Brutsche, M., Tiedt, R., Tichelli, A., Passamonti, F., Pietra, D., Cazzola, M. & Skoda, R.C. (2005) Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2. Blood, 106, 3374-3376.
    • (2005) Blood , vol.106 , pp. 3374-3376
    • Kralovics, R.1    Teo, S.S.2    Buser, A.S.3    Brutsche, M.4    Tiedt, R.5    Tichelli, A.6    Passamonti, F.7    Pietra, D.8    Cazzola, M.9    Skoda, R.C.10
  • 14
    • 38349178680 scopus 로고    scopus 로고
    • Differential GATA Factor Stabilities: implications for chromatin occupancy by structurally similar transcription factors
    • Lurie, L.J., Boyer, M.E., Grass, J.A. & Bresnick, E.H. (2008) Differential GATA Factor Stabilities: implications for chromatin occupancy by structurally similar transcription factors. Biochemistry, 47, 859-869.
    • (2008) Biochemistry , vol.47 , pp. 859-869
    • Lurie, L.J.1    Boyer, M.E.2    Grass, J.A.3    Bresnick, E.H.4
  • 16
    • 84861780038 scopus 로고    scopus 로고
    • Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis
    • Mascarenhas, J. & Hoffman, R. (2012) Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis. Clinical Cancer Research, 18, 3008-3014.
    • (2012) Clinical Cancer Research , vol.18 , pp. 3008-3014
    • Mascarenhas, J.1    Hoffman, R.2
  • 17
    • 83055198376 scopus 로고    scopus 로고
    • Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors
    • Morgillo, F., Martinelli, E., Troiani, T., Orditura, M., De Vita, F. & Ciardiello, F. (2011) Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors. PLoS ONE, 6, e28841.
    • (2011) PLoS ONE , vol.6
    • Morgillo, F.1    Martinelli, E.2    Troiani, T.3    Orditura, M.4    De Vita, F.5    Ciardiello, F.6
  • 18
    • 0035807221 scopus 로고    scopus 로고
    • Src directly tyrosine-phosphorylates STAT5 on its activation site and is involved in erythropoietin-induced signaling pathway
    • Okutani, Y., Kitanaka, A., Tanaka, T., Kamano, H., Ohnishi, H., Kubota, Y., Ishida, T. & Takahara, J. (2001) Src directly tyrosine-phosphorylates STAT5 on its activation site and is involved in erythropoietin-induced signaling pathway. Oncogene, 20, 6643-6650.
    • (2001) Oncogene , vol.20 , pp. 6643-6650
    • Okutani, Y.1    Kitanaka, A.2    Tanaka, T.3    Kamano, H.4    Ohnishi, H.5    Kubota, Y.6    Ishida, T.7    Takahara, J.8
  • 21
    • 62449283132 scopus 로고    scopus 로고
    • Sustained Src inhibition results in signal transducer and activator of transcription 3 (STAT3) activation and cancer cell survival via altered Janus-activated kinase-STAT3 binding
    • Sen, B., Saigal, B., Parikh, N., Gallick, G. & Johnson, F.M. (2009) Sustained Src inhibition results in signal transducer and activator of transcription 3 (STAT3) activation and cancer cell survival via altered Janus-activated kinase-STAT3 binding. Cancer Research, 69, 1958-1965.
    • (2009) Cancer Research , vol.69 , pp. 1958-1965
    • Sen, B.1    Saigal, B.2    Parikh, N.3    Gallick, G.4    Johnson, F.M.5
  • 22
    • 3142676436 scopus 로고    scopus 로고
    • Overriding imatinib resistance with a novel ABL kinase inhibitor
    • Shah, N.P., Tran, C., Lee, F.Y., Chen, P., Norris, D. & Sawyers, C.L. (2004) Overriding imatinib resistance with a novel ABL kinase inhibitor. Science, 305, 399-401.
    • (2004) Science , vol.305 , pp. 399-401
    • Shah, N.P.1    Tran, C.2    Lee, F.Y.3    Chen, P.4    Norris, D.5    Sawyers, C.L.6
  • 24
    • 0034745354 scopus 로고    scopus 로고
    • Bag1-Hsp70 mediates a physiological stress signalling pathway that regulates Raf-1/ERK and cell growth
    • Song, J., Takeda, M. & Morimoto, R.I. (2001) Bag1-Hsp70 mediates a physiological stress signalling pathway that regulates Raf-1/ERK and cell growth. Nature Cell Biology, 3, 276-282.
    • (2001) Nature Cell Biology , vol.3 , pp. 276-282
    • Song, J.1    Takeda, M.2    Morimoto, R.I.3
  • 25
    • 84861409093 scopus 로고    scopus 로고
    • Emerging treatment options for the treatment of neuroblastoma: potential role of perifosine
    • Sun, W. & Modak, S. (2012) Emerging treatment options for the treatment of neuroblastoma: potential role of perifosine. OncoTargets and Therapy, 5, 21-29.
    • (2012) OncoTargets and Therapy , vol.5 , pp. 21-29
    • Sun, W.1    Modak, S.2
  • 27
    • 44349140532 scopus 로고    scopus 로고
    • Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy
    • Tefferi, A. (2008) Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy. American Journal of Hematology, 83, 491-497.
    • (2008) American Journal of Hematology , vol.83 , pp. 491-497
    • Tefferi, A.1
  • 28
    • 80054028202 scopus 로고    scopus 로고
    • Long-term outcome of treatment with ruxolitinib in myelofibrosis
    • Tefferi, A., Litzow, M.R. & Pardanani, A. (2012) Long-term outcome of treatment with ruxolitinib in myelofibrosis. New England Journal of Medicine, 365, 1455-1457.
    • (2012) New England Journal of Medicine , vol.365 , pp. 1455-1457
    • Tefferi, A.1    Litzow, M.R.2    Pardanani, A.3
  • 29
    • 22144452197 scopus 로고    scopus 로고
    • A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
    • Ugo, V., James, C. & Vainchenker, W. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Med Sci (Paris), 21, 669-670.
    • (2005) Med Sci (Paris) , vol.21 , pp. 669-670
    • Ugo, V.1    James, C.2    Vainchenker, W.3
  • 35
    • 49649108912 scopus 로고    scopus 로고
    • Role of acetylation and extracellular location of heat shock protein 90alpha in tumor cell invasion
    • Yang, Y., Rao, R., Shen, J., Tang, Y., Fiskus, W., Nechtman, J., Atadja, P. & Bhalla, K. (2008) Role of acetylation and extracellular location of heat shock protein 90alpha in tumor cell invasion. Cancer Research, 68, 4833-4842.
    • (2008) Cancer Research , vol.68 , pp. 4833-4842
    • Yang, Y.1    Rao, R.2    Shen, J.3    Tang, Y.4    Fiskus, W.5    Nechtman, J.6    Atadja, P.7    Bhalla, K.8


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.